Indeed, almost one-third of MM patients have genetic alterations in CRBN by the time they are refractory to IMiDs (both lenalidomide and pomalidomide), and these genetic changes are associated with inferior outcomes [2, 17–21]. The gene discussed is CRBN; the disease is Miyoshi myopathy.